VEGFA and age-related macular degeneration: Considering the large number of individuals infected with HTLV-1 and the promising application of anti-VEGF treatments for ocular neovascularization–related diseases such as AMD, the absence of such studies has undoubtedly increased the likelihood of HTLV-1–associated ocular diseases occurring in HTLV-1 carriers who could benefit from anti-VEGF therapy.